Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte Corporation (INCY)'s Oral JAK1 Inhibitor in Patients With Active Rheumatoid Arthritis  
10/29/2013 10:04:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor. These results were presented today at the 2013 American College of Rheumatology / Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting being held in San Diego, CA, from Oct. 25 to 30, 2013.

Help employers find you! Check out all the jobs and post your resume.